Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Farzan

Showing results (1-10 of 162) with videos related to

Pageof 17
Sort By:
Nature Biotechnology|November 10, 2006
Tyrosine sulfate trapped by amberHyeryun Choe, Michael Farzan
Methods in Enzymology|June 2, 2009
Chapter 7. Tyrosine sulfation of HIV-1 coreceptors and other chemokine receptorsHyeryun Choe, Michael Farzan
Molecular Therapy. Methods & Clinical Development|December 11, 2025
Toward CAR-B cells for HIV-1 therapyYiming Yin, Michael Farzan
Science (New York, N.Y.)|April 30, 2021
How SARS-CoV-2 first adapted in humansHyeryun Choe, Michael Farzan
Nature Reviews. Immunology|December 15, 2012
The broad-spectrum antiviral functions of IFIT and IFITM proteinsMichael S Diamond, Michael Farzan
Pharmaceuticals (Basel, Switzerland)|December 28, 2021
Correction: Tickner, Z.J.; Farzan, M. Riboswitches for Controlled Expression of Therapeutic Transgenes Delivered by Adeno-Associated Viral Vectors. <i>Pharmaceuticals</i> 2021, <i>14</i>, 554Zachary J Tickner, Michael Farzan
Current Opinion in HIV and AIDS|April 20, 2017
Engineering antibody-like inhibitors to prevent and treat HIV-1 infectionMatthew R Gardner, Michael Farzan
Pharmaceuticals (Basel, Switzerland)|July 2, 2021
Riboswitches for Controlled Expression of Therapeutic Transgenes Delivered by Adeno-Associated Viral VectorsZachary J Tickner, Michael Farzan
Advances in Experimental Medicine and Biology|October 14, 2006
Insights from the association of SARS-CoV S-protein with its receptor, ACE2Wenhui Li, Hyeryun Choe, Michael Farzan
Nature Reviews. Microbiology|May 6, 2025
SARS-CoV-2 spike protein: structure, viral entry and variantsBing Chen, Michael Farzan, Hyeryun Choe
Pageof 17

Showing results (1-10 of 162) with videos related to

Sort By:
Pageof 17
Nature Biotechnology|November 10, 2006
Tyrosine sulfate trapped by amberHyeryun Choe, Michael Farzan
Methods in Enzymology|June 2, 2009
Chapter 7. Tyrosine sulfation of HIV-1 coreceptors and other chemokine receptorsHyeryun Choe, Michael Farzan
Molecular Therapy. Methods & Clinical Development|December 11, 2025
Toward CAR-B cells for HIV-1 therapyYiming Yin, Michael Farzan
Science (New York, N.Y.)|April 30, 2021
How SARS-CoV-2 first adapted in humansHyeryun Choe, Michael Farzan
Nature Reviews. Immunology|December 15, 2012
The broad-spectrum antiviral functions of IFIT and IFITM proteinsMichael S Diamond, Michael Farzan
Pharmaceuticals (Basel, Switzerland)|December 28, 2021
Correction: Tickner, Z.J.; Farzan, M. Riboswitches for Controlled Expression of Therapeutic Transgenes Delivered by Adeno-Associated Viral Vectors. <i>Pharmaceuticals</i> 2021, <i>14</i>, 554Zachary J Tickner, Michael Farzan
Current Opinion in HIV and AIDS|April 20, 2017
Engineering antibody-like inhibitors to prevent and treat HIV-1 infectionMatthew R Gardner, Michael Farzan
Pharmaceuticals (Basel, Switzerland)|July 2, 2021
Riboswitches for Controlled Expression of Therapeutic Transgenes Delivered by Adeno-Associated Viral VectorsZachary J Tickner, Michael Farzan
Advances in Experimental Medicine and Biology|October 14, 2006
Insights from the association of SARS-CoV S-protein with its receptor, ACE2Wenhui Li, Hyeryun Choe, Michael Farzan
Nature Reviews. Microbiology|May 6, 2025
SARS-CoV-2 spike protein: structure, viral entry and variantsBing Chen, Michael Farzan, Hyeryun Choe
Pageof 17